The UCLA Translational Pathology Core Laboratory Shared Resource (TPCL SR), a College of American Pathologists (CAP) accredited biobank, provides pathology services essential for basic, translational and clinical cancer research. Remnant human tissue procurement and distribution, histology services (animal and human tissues, frozen and formalin-fixed paraffin embedded specimens, laser capture microdissection), immunohistochemistry and in-situ hybridization services, state-of-the-art digital pathology services (slide scanning and quantitative image analysis) and pathology consultation services (including aid with tissue selection, study design, IRB applications and interpretation of results) are currently available. The instrumentation, staff technical skills, quality and pathology expertise available in the TPCL are expansive and beyond the budget of most labs. In August 2012, TPCL became the fourth biorepository in the United States to be accredited by the College of American Pathologists (CAP). The TPCL Director, Drs. Sarah Dry (ZY) and Co-Director, Jonathan Said (ZY) are both Board Certified, practicing pathologists who conduct basic, translational and clinical research. They have led the successful application for CAP accreditation, supervised renovations of new laboratory space, implemented state-of-the-art biorepository software used by TPCL and written grants that funded the purchase of Definiens image analysis software and a Leica LMD 7000 laser capture microdissection scope. TPCL links researchers with appropriate subspecialty pathologists interested in developing collaborative research projects. Through hands-on instruction and consultation, TPCL endeavors to make researchers comfortable and confident in independently performing image analysis and laser capture microdissection;TPCL can also perform these services for a fee. TPCL usage has remained relatively constant since 2008, reflecting the critical need for our services. From 07/01/2011- 06/30/2012, the TPCL Shared Resource had 254 users, 138 of whom were JCCC members, representing eight Cancer Center Program Areas. Of the 138 member users, 105 had peer-reviewed funding and 33 did not have peer-reviewed funding.

Public Health Relevance

Translational research and personalized medicine requires high quality human biosamples. TPCL provides a College of American Pathologist's accredited biobank, plus standard pathology services (histology, immunohistochemistry, pathology consultation) and state-of-the-art pathology resources (automated digital analysis, digital slide scanning, laser capture microdissection) required for successful modern cancer research in a cost effective manner to UCLA researchers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications